医药生物周报:白癜风200亿潜在蓝海 关注康哲药业和泰恩康

华福证券有限责...
Jun 08, 2025

专题:中国白癜风患者超2200万人,创新药潜在市场空间或超200亿,近期或迎来重要催化:康哲芦可替尼NDA获受理上市在即,泰恩康CKBAII期数据预计Q3披露。中国白癜风患者超2200万人,影响患者的社交和人际关系、健康情况。白癜风现有疗法缺陷多,当前主流白癜风治疗药物包括钙调神经磷酸酶抑制剂、糖皮质激素等,在疗效、安全性和长期用药依从性方面或多或少存在缺陷,且现有化药均为off-label用药,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10